ZENYF - ZENYF STOCK NEWS

Zentek Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has expanded its management team and Advisory Board to enhance execution of its business plan. New appointments include Vivian Martin as Director of Regulatory Affairs, Raeme Sul as Director of Human Resources, and Ryan Shacklock as VP of Strategy, Business Development & Investor Relations. The company also added two production staff to meet the demand for ZENGuard pilot production. The Advisory Board gains experts Dr. Yingfu Li and Dr. Joseph Armand Korkis, strengthening its healthcare strategy focused on rapid detection technologies.

ZEN Graphene Solutions Ltd. has announced a name change to Zentek Ltd. following approval from shareholders during a meeting on September 27, 2021. The company's shares are set to trade under the new name on the TSX Venture Exchange starting November 1, 2021, while retaining the ticker symbol ZEN. This change comes as the company focuses on its innovative healthcare solutions, including a patent-pending antimicrobial coating and a rapid pathogen detection technology.

ZEN Graphene Solutions Ltd. will present a corporate overview during the Benzinga Global Small Cap Conference on October 27, 2021. CEO Greg Fenton is scheduled to deliver a presentation at 3:00 PM ET and will be available for one-on-one meetings throughout the event. ZEN focuses on developing next-gen healthcare solutions, including ZENGuard™, a patent-pending antimicrobial coating effective against COVID-19, and a rapid pathogen detection technology. For more details, visit www.ZENGraphene.com.

ZEN Graphene Solutions Ltd. (TSX-V:ZEN, OTC:ZENYF) has received final approval from the TSX Venture Exchange to change its classification from a mining issuer to an industrial, technology, or life sciences issuer. This change, approved by shareholders on September 27, 2021, reflects the Company's focus on nanotechnology solutions for healthcare. Effective October 18, 2021, this new classification aligns with ZEN's initiatives in the areas of prevention, detection, and treatment, including their ZENGuard antimicrobial coating and a rapid pathogen detection technology.

ZEN Graphene Solutions Ltd. (TSXV:ZEN)(OTC PINK:ZENYF) has applied for a listing on The Nasdaq Capital Market. This strategic move is expected to enhance liquidity, increase visibility, and ultimately boost shareholder value. The application is supported by Donohoe Advisory Associates LLC and is pending Nasdaq's approval and compliance with regulatory requirements. ZEN, focused on developing innovative healthcare solutions, is also commercializing ZENGuard^TM, an antimicrobial coating with significant efficacy against COVID-19.

ZEN Graphene Solutions Ltd. has announced the filing of a full international patent application for its ZENGuard™ compound, focusing on its antimicrobial properties in surgical masks. This strategic move aims to capitalize on global opportunities for the technology, which significantly reduces viable bacteria and virus transmission. The company emphasizes its commitment to innovating healthcare solutions, with Health Canada approval already in place. Additionally, ZEN has acquired exclusive global rights to a new technology from Guelph University for producing graphene oxide, enhancing its research and commercial capabilities.

ZEN Graphene Solutions has announced an accelerated expiry for its 2021 and 2020 common share purchase warrants due to the achievement of specified trading price conditions. The 2021 Warrants, initially due April 8, 2023 at $3.00 each, and the 2020 Warrants, due July 6, 2022 at $0.80 each, now expire on November 3, 2021. This decision follows the closing price of ZEN shares exceeding the required thresholds for ten consecutive trading days. Holders must exercise their warrants by 5:00 p.m. (Toronto time) on the expiry date to avoid voiding their warrants.

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) announces shareholder approval of key resolutions during its annual meeting on September 27, 2021. These include initiatives aimed at enhancing the company’s focus on nanotechnology and health sciences. CEO Greg Fenton expressed optimism for increased interest from U.S. investors. Furthermore, ZEN has enlisted CORE IR for investor relations and public relations to assist in expanding its market presence and explore potential U.S. listings. The company is also commercializing ZENGuard TM, an antimicrobial coating with 99% efficacy against pathogens.

ZEN Graphene Solutions Ltd. (TSXV:ZEN)(OTC PINK:ZENYF) announced a definitive commercial agreement with Trebor Rx for the manufacturing of ZENGuard™ enhanced personal protective equipment (PPE), including surgical masks and nitrile gloves. The Trebor Rx surgical mask boasts over 99.99% bacterial and viral filtration efficiency. CEO Greg Fenton highlighted the partnership's significant potential for enhancing safety in healthcare settings. ZEN is focused on nanotechnology solutions for healthcare, including antimicrobial coatings and pathogen detection technology.